Toralizumab

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease[1][2][3].

Product Specifications

CAS Number

[252662-47-8]

Product Name Alternative

IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

UNSPSC

12352203

Hazard Statement

H315-H319

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/toralizumab.html

Purity

99.57

Solubility

H2O

Smiles

[Toralizumab]

Molecular Weight

(145.66 kDa)

Precautions

P264-P280-P302+P352-P305+P351+P338-P362+P364

References & Citations

[1]Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8 (6) :e1096.|[2]Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46 (12) :3251-8.|[3]Murphy, G., & Isenberg, D. A. (2019) . New therapies for systemic lupus erythematosus - past imperfect, future tense. Nature reviews. Rheumatology, 15 (7), 403-412.|[4]Lassiter, G., et al., (2023) . TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 23 (8), 1171-1181.|[5]Xu, H., et al., (2003) . Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. Journal of immunology (Baltimore, Md.: 1950), 170 (5), 2776-2782.